Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma

Sponsor
Bayside Health
Study ID
NCT00163748
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open label pilot study of 40 evaluable patients receiving vinorelbine-gemcitabine combination chemotherapy with filgrastim support in an outpatient setting. Participating patients at the time of registration will have measurable relapsed or primary refractory lymphoma.

Key Dates

Start date
Feb 28, 2001
Status verified
Jan 2016
Primary completion
Nov 30, 2003
Completion
Nov 30, 2003

Study Design

Enrollment
40 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

To evaluate the efficacy and regimen related toxicity of the study treatment (vinorelbine and gemcitabine with filgrastim support).

Related Studies